Table 1 Characteristics at baseline
Variables | Unmatched cases | Matched cases | ||||
|---|---|---|---|---|---|---|
< 65Y, n = 71 | ≥ 65Y, n = 108 | P-value | < 65Y, n = 66 | ≥ 65Y, n = 66 | P-value | |
Sex, n (%) | 0.092 | 0.715 | ||||
Male | 64 (90.1) | 105 (97.2) | 61 (92.4) | 63 (95.5) | ||
Female | 7 (9.9) | 3 (2.8) | 5 (7.6) | 3 (4.5) | ||
ECOG performance status, n (%) | 0.001 | 0.189 | ||||
0 | 54 (76.1) | 56 (51.9) | 50 (75.8) | 56 (84.8) | ||
1 | 17 (23.9) | 52 (48.1) | 16 (24.2) | 10 (15.2) | ||
Smoking status, n (%) | 0.653 | 0.725 | ||||
Never | 30 (42.3) | 42 (38.9) | 27 (40.9) | 29 (43.9) | ||
Ever | 41 (57.7) | 66 (61.1) | 39 (59.1) | 37 (56.1) | ||
Drinking status, n (%) | 0.896 | 0.715 | ||||
Never | 48 (67.6) | 72 (66.7) | 44 (66.7) | 42 (63.6) | ||
Ever | 23 (32.4) | 36 (33.3) | 22 (33.3) | 24 (36.4) | ||
Diabetes mellitus, n (%) | 0.329 | 0.715 | ||||
Yes | 3 (4.2) | 10 (9.3) | 3 (4.5) | 5 (7.6) | ||
No | 68 (95.8) | 98 (90.7) | 63 (95.5) | 61 (92.4) | ||
Hypertension, n (%) | 0.548 | 0.262 | ||||
Yes | 20 (28.2) | 35 (32.4) | 18 (27.3) | 24 (36.4) | ||
No | 51 (71.8) | 73 (67.6) | 48 (72.7) | 42 (63.6) | ||
T stage, n (%) | 0.266 | 0.708 | ||||
T1b | 7 (9.9) | 3 (2.8) | 6 (9.1) | 3 (4.5) | ||
T1c | 8 (11.3) | 15 (13.9) | 8 (12.1) | 7 (10.6) | ||
T2a | 12 (16.9) | 17 (15.7) | 12 (18.2) | 14 (21.2) | ||
T2b | 18 (25.4) | 24 (22.2) | 17 (25.8) | 16 (24.2) | ||
T3 | 12 (16.9) | 30 (27.8) | 10 (15.2) | 16 (24.2) | ||
T4 | 14 (19.7) | 19 (17.6) | 13 (19.7) | 10 (15.2) | ||
N stage, n (%) | 0.243 | 0.106 | ||||
N0 | 3 (4.2) | 5 (4.6) | 3 (4.5) | 4 (6.1) | ||
N1 | 8 (11.3) | 23 (21.3) | 8 (12.1) | 16 (24.2) | ||
N2 | 59 (83.1) | 76 (70.4) | 54 (81.8) | 42 (63.6) | ||
N3 | 1 (1.4) | 4 (3.7) | 1 (1.5) | 4 (6.1) | ||
Clinical stage, n (%) | 0.771 | 0.896 | ||||
IIA | 2 (2.8) | 3 (2.8) | 2 (3.0) | 2 (3.0) | ||
IIB | 7 (9.9) | 14 (13.0) | 7 (10.6) | 10 (15.2) | ||
IIIA | 39 (54.9) | 51 (47.2) | 37 (56.1) | 34 (51.5) | ||
IIIB | 23 (32.4) | 40 (37.0) | 20 (30.3) | 20 (30.3) | ||
Pathology, n (%) | 0.027 | 0.189 | ||||
LUSC | 50 (70.4) | 91 (84.3) | 50 (75.8) | 56 (84.8) | ||
LUAD* | 21 (29.6) | 17 (15.7) | 16 (24.2) | 10 (15.2) | ||
Treatment cycle, n (%) | 0.396 | 0.278 | ||||
2 | 22 (31.0) | 37 (34.3) | 21 (31.8) | 23 (34.8) | ||
3 | 13 (18.3) | 12 (11.1) | 11 (16.7) | 5 (7.6) | ||
4 | 36 (50.7) | 59 (54.6) | 34 (51.5) | 38 (57.6) | ||
Immunotherapy regimes, n (%) | 0.523 | 0.786 | ||||
Camrelizumab, 200 mg | 25 (35.2) | 31 (28.7) | 22 (33.3) | 21 (31.8) | ||
Nivolumab, 200 mg | 9 (12.7) | 18 (16.7) | 8 (12.1) | 9 (13.6) | ||
Sintilimab, 200 mg | 9 (12.7) | 14 (13.0) | 9 (13.6) | 8 (12.1) | ||
Tislelizumab, 200 mg | 10 (14.1) | 24 (22.2) | 9 (13.6) | 14 (21.2) | ||
Pembrolizumab, 200 mg | 18 (25.4) | 21 (19.4) | 18 (27.3) | 14 (21.2) | ||